Promoted Content Promoted Content

X

Find Psychiatry/Psychology Drugs in Phase II Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: COMP360

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 28, 2021

            Details:

            The trial is controlled, double-blinded, dose-ranging study, investigating the safety & efficacy of psilocybin therapy & comparing 25mg and 10mg dose of COMP360 psilocybin with 1mg dose, administered in conjunction with psychological support from specially trained therapists.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: COMP360

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2021

            Details:

            Participants were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29). The drug was administered simultaneously to upto six participants, who all received 1:1 psychological support from trained therapists throughout the session.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N-methyl amisulpride

            Therapeutic Area: Psychiatry/Psychology Product Name: LB-102

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Financing September 25, 2020

            Details:

            Proceeds to enable the Company’s continued clinical development of LB-102 for the treatment of schizophrenia.